摘要
目的探讨应用血管紧张素II受体拮抗剂/噻嗪类利尿剂(ARB/HCTZ)类新型单片复方制剂(single pill combination,SPC)治疗慢性心衰的有效性及安全性。方法采用抽签法随机抽取116例慢性心衰患者,分别采用ARB/HCTZ类新型SPC与常规药物治疗,对比两种不同方法治疗6个月后患者的服药顺从指数(CI)、不良反应发生率、心衰再入院率。结果与常规药物治疗相比,ARB/HCTZ类SPC组患者CI较高,不良反应发生率及心衰再入院率较低,差异均有统计学意义(P<0.05)。结论合理使用新型单片复方降压制剂可通过改善慢性心衰患者服药依从性,较常规治疗能更安全持续有效地控制慢性心衰。
Objective To investigate the effectiveness and reliability of a new single pill combination （ SPC） that contained and （ ARB/HCTZ） in treatment of chronic heart failure .Methods One hundred and sixteen patients with chronic heart failure were divided into two groups treated with a new SPC and conventional drugs ,respectively.The compliance index （CI）,the rate of adverse drug reactions and readmission due to heart failure were observed after 6 months of treatment .Results Compared to the control group , the SPC group had higher compliance index ,and lower rate of adverse drug reactions and readmission （ P〈0.05 ） .Conclusion Chro-nic heart failure may be controlled more consistently ,safely and efficiently via higher medication compliance by reasonable use of the new SPC.
出处
《实用医院临床杂志》
2014年第5期146-148,共3页
Practical Journal of Clinical Medicine
